Aurobindo Pharma Share Price
Mid Cap | Pharmaceuticals and health care | NSE: AUROPHARMA | BSE: 524804
₹1,105.35 
-71.00 (-6.04 %)
Last Updated: 04 Apr 2025 03:59 PM
BEARISH
Overview
Open (₹) 1,177.00
High (₹) 1,179.45
Low (₹) 1,050.10
Prev. Close (₹) 1,176.35
Volume 71,51,520
VWAP (₹) 1,060.93
ROCE (%) 14.84
Industry P/E 44.73
TTM P/E 18.39
P/B Ratio 2.17
Market Cap (₹) Cr.64,198.91
Dividend Yield (%)0.41
EPS (₹) 54.16
ROE10.63%
Sales Growth (%) 16.68
Profit Growth (%)64.29
Day Range
1,179.451,179.45
52 Week Range
1,030.651,592.55
Historical Returns
Returns (6M)
-24.63 %
Returns (1Y)
-1.63 %
Returns (3Y)
56.94 %
Returns (5Y)
148 %
Returns (6M)
-24.63 %
Returns (1Y)
-1.63 %
Returns (3Y)
56.94 %
Returns (5Y)
148 %
SWOT Analysis
- Effectively using its capital to generate profits - ROCE improved in the last year
- Company with (64.62%) TTM EPS Growth
- Company with Low Debt
- Book value per share improving over the last 2 years
- Efficient in managing Assets to generate Profits - ROA improved since last year
- Company with 64.62% positive TTM EPS growth
- Increasing Annual Revenue for Past 2 Years
- Price above the pivot point indicates bullish sentiment.
Technicals
Technical Rating
BEARISHRSI 68.09
MFI 21.17
ATR 45.42
Commodity Channel Index -162.03
ROC125 -32.30
ROC21 -10.55
Williams %R -96.39
Resistance & Support
| Type | Resistance 1 | Resistance 2 | Resistance 3 | PP | Support 1 | Support 2 | Support 3 |
|---|---|---|---|---|---|---|---|
| Current | 1,072.00 | 1,085.70 | 1,095.05 | 1,062.65 | 1,048.95 | 1,039.60 | 1,025.90 |
| Week Ago | 1,129.15 | 1,143.15 | 1,159.45 | 1,112.85 | 1,098.85 | 1,082.55 | 1,068.55 |
| Month Ago | 1,164.36 | 1,190.13 | 1,204.81 | 1,149.68 | 1,123.91 | 1,109.23 | 1,083.46 |
EMA & SMA
1105.35
Current Price
Bullish Moving Averages
2
Bearish Moving Averages
18
5 Day 1096.65
9 Day 1125.15
10 Day 1118.61
12 Day 1128.57
14 Day 1135.49
20 Day 1141.22
26 Day 1153.18
50 Day 1198.70
100 Day 1272.19
200 Day 1320.07
Deals & Announcements
Bulk and Block Deals
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| SOCIETE GENERALE | block | Sell | 25 Jan, 2024 | ₹1,160.10 | 1,07,558 | NSE |
| MARSHALL WACE INVESTMENT STRATEGIES TOPS FUND | block | Buy | 25 Jan, 2024 | ₹1,160.10 | 44,921 | NSE |
| MARSHALL WACE INVESTMENT STRATEGIES MARKET NEUTRAL TOPS FUND | block | Buy | 25 Jan, 2024 | ₹1,160.10 | 8,134 | NSE |
| MARSHALL WACE INVESTMENT STRATEGIES SYSTEMATIC ALPHA PLUS FUND | block | Buy | 25 Jan, 2024 | ₹1,160.10 | 862 | NSE |
| MARSHALL WACE INVESTMENT STRATEGIES EUREKA FUND | block | Buy | 25 Jan, 2024 | ₹1,160.10 | 53,641 | NSE |
| ISHARES CORE EMERGING MARKETS MAURITIUS CO | block | Sell | 14 Nov, 2022 | ₹489.30 | 2,97,308 | NSE |
| ISHARES CORE MSCI EMERGING MARKETS ETF | block | Buy | 14 Nov, 2022 | ₹489.30 | 2,97,308 | NSE |
| ISHARES CORE EMERGING MARKETS MAURITIUS CO | block | Sell | 03 Nov, 2022 | ₹557.30 | 2,97,309 | NSE |
| ISHARES CORE MSCI EMERGING MARKETS ETF | block | Buy | 03 Nov, 2022 | ₹557.30 | 2,97,309 | NSE |
| ISHARES CORE EMERGING MARKETS MAURITIUS CO | block | Sell | 03 Oct, 2022 | ₹510.60 | 3,19,654 | NSE |
Insider Trading
| Date | Name | Action | Avg. Price | Quantity | Deal Value |
|---|---|---|---|---|---|
| 01 Apr, 2024 | RPR Sons Advisors Pvt.Ltd. Mrs.P.Suneela Rani jointly holding | Revoke | ₹1,088.75 | 1,16,35,862 | NSE |
| 28 Mar, 2024 | RPR Sons Advisors Pvt.Ltd. Mrs.P.Suneela Rani jointly holding | Pledge | ₹1,053.05 | 1,67,00,000 | NSE |
| 25 Mar, 2024 | A.Janardhana Kamath | Disposal | ₹1,013.49 | 6,000 | NSE |
| 05 Mar, 2024 | Pavankumar PS | Disposal | ₹1,022.00 | 1,000 | NSE |
| 01 Mar, 2024 | Chandrasekhar Reddy Kandati | Disposal | ₹1,047.39 | 2,000 | NSE |
| 26 Feb, 2024 | RPR Sons Advisors Pvt.Ltd. Mrs.P.Suneela Rani jointly holding | Revoke | ₹1,043.80 | 23,00,000 | NSE |
| 26 Feb, 2024 | RPR Sons Advisors Pvt.Ltd. Mrs.P.Suneela Rani jointly holding | Revoke | ₹1,043.80 | 1,00,50,000 | NSE |
| 23 Feb, 2024 | Pavankumar PS | Disposal | ₹1,025.00 | 1,000 | NSE |
| 21 Feb, 2024 | Ambati Rama Mohan Rao | Disposal | ₹1,020.00 | 5,000 | NSE |
| 21 Feb, 2024 | K.Nagaraju | Disposal | ₹1,048.46 | 5,000 | NSE |
Corporate Actions
| Announcement Date | Subject | Ex - Date | Record Date |
|---|---|---|---|
| 07 Feb, 2024 | Rs.1.5000 per share(150%)Second Interim Dividend | 20 Feb, 2024 | 20 Feb, 2024 |
| 02 Nov, 2023 | Rs.3.0000 per share(300%)First Interim Dividend | 20 Nov, 2023 | 20 Nov, 2023 |
| 03 Feb, 2023 | Rs.3.0000 per share(300%)Interim Dividend | 17 Feb, 2023 | 17 Feb, 2023 |
Announcements
| Date | Source | Detail |
|---|---|---|
| 02 Apr, 2025 | NSE India | Aurobindo Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 |
| 02 Apr, 2025 | BSE India | Submission of Certificate under regulation 74 (5) of SEBI (DP) Regulations for the Quarter ended March 31, 2025 |
| 31 Mar, 2025 | NSE India | Aurobindo Pharma Limited has informed the Exchange about General Updates |
| 31 Mar, 2025 | BSE India | Submission of disclosure of Cautionary email received from the stock exchanges regarding delay in intimation of Schedule of Investors meet again in the prescribed format |
| 28 Mar, 2025 | NSE India | Aurobindo Pharma Limited has informed the Exchange about General Updates |
| 28 Mar, 2025 | BSE India | Intimation of Cautionary Email received from the stock Exchange regarding delay in intimation of Schedule of Investors Meet. |
| 28 Mar, 2025 | NSE India | AUROBINDO PHARMA LIMITED has informed the Exchange regarding Update-Acquisition/Scheme/Sale/Disposal-XBRL |
| 28 Mar, 2025 | NSE India | Aurobindo Pharma Limited has informed the Exchange about Acquisition |
| 28 Mar, 2025 | BSE India | Update on solar Power purchase Agreement and acquisition upto 26% stake in Swarnaakshu Solar Power Private Limited |
| 27 Mar, 2025 | NSE India | AUROBINDO PHARMA LIMITED has informed the Exchange about Closure of Trading Window |
Board Meetings
| Purpose | Details | Meeting Date | Broadcast Date |
|---|---|---|---|
| Quarterly Results | -- | 20 Jan, 2025 | 06 Feb, 2025 |
| Quarterly Results | -- | 05 Nov, 2024 | 09 Nov, 2024 |
| Quarterly Results | -- | 01 Aug, 2024 | 10 Aug, 2024 |
| Buy Back of Shares | To consider buyback for equity shares | 18 Jul, 2024 | 18 Jul, 2024 |
| Audited Results | -- | 30 May, 2024 | 25 May, 2024 |
| Quarterly Results & Interim Dividend | -- | 30 May, 2024 | 10 Feb, 2024 |
| Quarterly Results & Interim Dividend | -- | 30 May, 2024 | 09 Nov, 2023 |
| Quarterly Results | -- | 30 May, 2024 | 12 Aug, 2023 |
| Audited Results | -- | 30 May, 2024 | 27 May, 2023 |
| Quarterly Results & Interim Dividend | -- | 30 May, 2024 | 09 Feb, 2023 |
Share Holding Pattern
| Owner Name | Sept, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
|---|---|---|---|---|---|
| Promoter Group | 51.82% | 51.83% | 51.83% | 51.83% | 51.94% |
| Foreign Institutions + | 16.59% | 20.72% | 22.31% | 21.37% | 24.99% |
| Domestic Institutions + | 25.14% | 20.6% | 14.9% | 16.48% | 12.61% |
| Government | 0% | 0% | 0% | 0% | 0% |
| Public | 6.45% | 6.85% | 10.96% | 10.32% | 10.46% |
| Others | 0% | 0% | 0% | 0% | 0% |
About Aurobindo Pharma
Aurobindo Pharma is a Public Limited Listed company incorporated on 26/12/1986 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24239TG1986PLC015190 and registration number is 015190. Currently Company is involved in the business activities of Manufacture of other pharmaceutical and botanical products like hina powder etc.. Company’s Total Operating Revenue is Rs. 10645.64 Cr. and Equity Capital is Rs. 58.59 Cr. for the Year ended 31/03/2024. Read More
Parent Organisation
Not Applicable
Founded
1986
Managing Director
-- --
NSE Symbol
AUROPHARMA
Aurobindo Pharma Management
| Name | Designation |
|---|---|
| Mr. M Ramasubramanian Kumar | Chairman & Ind.Dire (Non-Exe) |
| Mr. K Nithyananda Reddy | Vice Chairman & Mng.Director |
| Mr. M Madan Mohan Reddy | Whole Time Director |
| Mr. P V Ramprasad Reddy | Non Executive Director |
| Dr. Satakarni Makkapati | Non Executive Director |
| Mr. P Sarath Chandra Reddy | Non Executive Director |
| Mr. Girish P Vanvari | Independent Director |
| Mrs. Savita Mahajan | Independent Director |
| Mr. Santanu Mukherjee | Independent Director |
| Dr. Deepali Pant Joshi | Independent Director |
Peer Comparison
| Stocks | Market Cap | Market Price | 52 Week Low-High |
|---|---|---|---|
| Sun Pharmaceutical Industries | ₹4,10,130.32 | ₹1,709.35  ₹1,770.00(-3.43%) | ₹1,376.750 - ₹1,960.200 |
| Divi's Laboratories | ₹1,45,552.44 | ₹5,482.85 ₹5,763.00(-4.86%) | ₹3,613.550 - ₹6,448.750 |
| Cipla | ₹1,14,298.01 | ₹1,415.25 ₹1,495.70(-5.38%) | ₹1,317.600 - ₹1,702.000 |
| Torrent Pharmaceuticals | ₹1,11,230.09 | ₹3,286.50  ₹3,247.70(1.19%) | ₹2,508.650 - ₹3,589.950 |
| Mankind Pharma | ₹1,01,131.25 | ₹2,451.20 ₹2,427.70(0.97%) | ₹1,910.100 - ₹3,050.000 |
FAQs on Aurobindo Pharma
What is the share price of Aurobindo Pharma?
The share price of Aurobindo Pharma on 04 Apr, 2025 is ₹ 1,105.35.
What is 52W high and 52W low share price of Aurobindo Pharma?
The highest and lowest 52W share prices of Aurobindo Pharma are ₹ 1592.550 and ₹ 1030.650
What is the market cap of Aurobindo Pharma?
The market capitalization of Aurobindo Pharma as of 04 Apr, 2025 is ₹ 64,198.91 Crores
What is the P/E ratio of Aurobindo Pharma?
The current P/E ratio of Aurobindo Pharma as of 04 Apr, 2025 is 44.73
What is the PB ratio of Aurobindo Pharma?
The PB ratio of Aurobindo Pharma as of 04 Apr, 2025 is 2.17
Top Gainers
₹18.07
₹15.14 (0.19%)
₹66.60
₹57.80 (0.15%)
₹88.74
₹73.95 (0.20%)
₹197.50
₹167.35 (0.18%)
Top Losers
₹307.35
₹368.55 (-0.17%)
₹108.20
₹127.00 (-0.15%)
₹0.54
₹1.03 (-0.48%)
₹2,705.55
₹3,206.90 (-0.16%)
Market Indices
Sensex
₹75,364.69
₹76,295.36 (-0.01%)